Exhibit 10.1



 EXHIBIT 10.1 

 
  

 
 KAMAN CORPORATION 

(a Connecticut corporation) 
 $100,000,000 
 3.25% Convertible Senior Notes due 2017 

PURCHASE AGREEMENT 

November 15, 2010 
  

 
  







 EXECUTION VERSION 

KAMAN CORPORATION 

(a Connecticut corporation) 
 $100,000,000 
 3.25% Convertible Senior Notes due 2017 

PURCHASE AGREEMENT 
 November 15, 2010 
 Merrill Lynch, Pierce, Fenner & Smith Incorporated 

RBS Securities Inc. 
 as Representatives of the
several Initial Purchasers 
 c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated 

One Bryant Park 
 New York, 

New York 10036 
 Ladies and Gentlemen:

 KAMAN CORPORATION, a Connecticut corporation (the “Company”), confirms its agreement with Merrill Lynch, Pierce,
Fenner & Smith Incorporated (“Merrill Lynch”) and each of the other Initial Purchasers named in Schedule A hereto (collectively, the “Initial Purchasers,” which term shall also include any initial purchaser substituted
as hereinafter provided in Section 10 hereof), for whom Merrill Lynch and RBS Securities Inc. are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase
by the Initial Purchasers, acting severally and not jointly, of the respective principal amounts set forth in said Schedule A of $100,000,000 aggregate principal amount of the Company’s 3.25% Convertible Senior Notes due 2017 (the
“Initial Securities”) and (ii) the grant by the Company to the Initial Purchasers, acting severally and not jointly, of the option to purchase all or any part of an additional $15,000,000 aggregate principal amount of its 3.25%
Convertible Senior Notes due 2017 (the “Option Securities” and, together with the Initial Securities, the “Securities”) to cover overallotments. The Securities are to be issued pursuant to an indenture dated as of
November 19, 2010 (the “Indenture”) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”). 
 The Company understands that the Initial Purchasers propose to make an offering of the Securities on the terms and in the manner set forth in this Purchase Agreement (this “Agreement”) and
agrees that the Initial Purchasers may resell, subject to the conditions set forth herein, all or a portion of the Securities to purchasers (“Subsequent Purchasers”) at any time after this Agreement has been executed and delivered. The
Securities are to be offered and sold through the Initial Purchasers without being registered under the Securities Act of 1933, as amended (the “1933 Act”), in reliance upon exemptions therefrom. Pursuant to the terms of the
Securities and the Indenture, investors that acquire Securities may only resell or otherwise transfer such Securities if such Securities are hereafter registered under the 1933 Act or if an exemption from the registration requirements of the
1933 Act is available (including the exemption afforded by Rule 144A (“Rule 144A”) of the rules and regulations promulgated under the 1933 Act (the “1933 Act Regulations”) by the Securities and Exchange
Commission (the “Commission”)). 







 The Company has prepared and delivered to each Initial Purchaser copies of a preliminary
offering memorandum dated November 15, 2010 (the “Preliminary Offering Memorandum”) and has prepared and will deliver to each Initial Purchaser, on the date hereof or the next succeeding day, copies of a final offering memorandum
dated November 15, 2010 (the “Final Offering Memorandum”), each for use by such Initial Purchaser in connection with its solicitation of purchases of, or offering of, the Securities. “Offering Memorandum” means, with respect
to any date or time referred to in this Agreement, the most recent offering memorandum (whether the Preliminary Offering Memorandum or the Final Offering Memorandum, or any amendment or supplement to either such document), including exhibits thereto
and any documents incorporated therein by reference, which has been prepared and delivered by the Company to the Initial Purchasers in connection with their solicitation of purchases of, or offering of, the Securities. The Company will prepare a
final term sheet reflecting the final terms of the Securities, in the form set forth in Schedule B hereto (the “Final Term Sheet”), and will deliver such Final Term Sheet to the Initial Purchasers in connection with their solicitation of
purchases of, or offering of, the Securities. The Company agrees that, unless it obtains the prior written consent of the Representatives, it will not make any offer relating to the Securities by any written materials other than the Offering
Memorandum and the Issuer Written Information. “Issuer Written Information” means (i) any writing intended for general distribution to investors as evidenced by its being specified in Schedule C hereto, including the Final Term Sheet,
and (ii) any “road show” that is a “written communication” within the meaning of the 1933 Act and that has been previously reviewed and approved for distribution by the Company. “General Disclosure Package” means
the Preliminary Offering Memorandum and any Issuer Written Information specified on Schedule C hereto and issued at or prior to 4:00 P.M., New York City time, on November 15, 2010 or such other time as agreed by the Company and Merrill Lynch
(such date and time, the “Applicable Time”). 
 All references in this Agreement to financial statements and schedules
and other information which is “contained,” “included” or “stated” in the Offering Memorandum (or other references of like import) shall be deemed to mean and include all such financial statements and schedules and
other information which are incorporated by reference in the Offering Memorandum; and all references in this Agreement to amendments or supplements to the Offering Memorandum shall be deemed to mean and include the filing of any document under the
Securities Exchange Act of 1934 (the “1934 Act”) which is incorporated by reference in the Offering Memorandum. 

SECTION 1. Representations and Warranties. 
 (a) Representations and Warranties by the Company. The Company represents and warrants to each Initial Purchaser as of the date hereof, the Applicable Time, the Closing Time (as defined below) and
any Date of Delivery (as defined below), except in the case of representations and warranties that by their terms speak as of a specified date, in which instance the Company represents and warrants as of such specified date, and agrees with each
Initial Purchaser, as follows: 
 (i) General Disclosure Package; Rule 144A Eligibility. The Company
hereby confirms that it has authorized the use of the General Disclosure Package, including the Preliminary Offering Memorandum and the Final Term Sheet, and the Final Offering Memorandum in connection with the offer and sale of the Securities by
the Initial Purchasers. The Securities are eligible for resale pursuant to Rule 144A and will not be, at the Closing Time, of the same class as securities listed on a national securities exchange registered under Section 6 of the
1934 Act, or quoted in a U.S. automated interdealer quotation system. 
 (ii) No Registration Required;
No General Solicitation. Subject to compliance by the Initial Purchasers with the representations and warranties of the Initial Purchasers and the procedures set forth in Section 6 hereof, it is not necessary in connection with the offer,
sale and 

  
 2 








 
delivery of the offered Securities to the Initial Purchasers and to each Subsequent Purchaser in the manner contemplated by this Agreement and the Offering Memorandum to register the Securities
under the 1933 Act or to qualify the Indenture under the Trust Indenture Act of 1939, as amended (the “1939 Act”). None of the Company, its affiliates controlled by the Company or any person acting on its or any of their behalf (other
than the Initial Purchasers, as to whom the Company makes no representation) has engaged, in connection with the offering of the offered Securities, in any form of general solicitation or general advertising within the meaning of Rule 502(c)
under the 1933 Act Regulations. 
 (iii) Accurate Disclosure. As of the Applicable Time, neither
(A) the General Disclosure Package nor (B) any Issuer Written Information, when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits or will
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Final Offering Memorandum, as of its date, at the Closing Time or at any Date of
Delivery, did not, does not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The documents incorporated or deemed to be incorporated by reference in the General Disclosure Package and the Final Offering Memorandum, when such documents incorporated by reference were filed with the Commission, when read together with the other
information in the General Disclosure Package or the Final Offering Memorandum, as the case may be, did not, does not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. 
 The
representations and warranties in this subsection shall not apply to statements in or omissions from the General Disclosure Package or the Final Offering Memorandum made in reliance upon and in conformity with written information furnished to the
Company by any Initial Purchaser through Merrill Lynch expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in the first paragraph under the heading “Plan of
Distribution–Price Stabilization, Short Positions” in the Offering Memorandum (collectively, the “Initial Purchaser Information”). 
 (iv) Incorporation of Documents by Reference. The documents incorporated or deemed to be incorporated by reference in the Offering Memorandum, when they became effective or at the time they were or
hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act and the rules and regulations of the Commission under the 1934 Act (the “1934 Act Regulations”). 

(v) Independent Accountants. The accountants who certified the financial statements and supporting schedules
included in the Offering Memorandum are independent public accountants as required by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company Accounting Oversight Board. 

(vi) Financial Statements; Non-GAAP Financial Measures. The financial statements included or incorporated by
reference in the General Disclosure Package and the Final Offering Memorandum, together with the related schedules and notes, present fairly the financial position of the Company and its consolidated subsidiaries at the dates indicated and the
statement of operations, stockholders’ equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting
principles (“GAAP”) applied on a consistent basis throughout the 

  
 3 








 
periods involved. The supporting schedules, if any, present fairly in accordance with GAAP the information required to be stated therein. The selected financial data and the summary financial
information included in the Offering Memorandum present fairly the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or
pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Offering Memorandum under the 1933 Act or the 1933 Act Regulations. All disclosures contained in the General Disclosure Package or
the Final Offering Memorandum, or incorporated by reference therein, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the 1934 Act and Item 10
of Regulation S-K of the 1933 Act, to the extent applicable. 
 (vii) No Material Adverse Change in
Business. Except as otherwise stated therein, since the respective dates as of which information is given in the General Disclosure Package or the Final Offering Memorandum, (A) there has been no material adverse change in the condition,
financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a “Material Adverse Effect”),
(B) there have been no transactions entered into by the Company or any of its subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as one enterprise,
and (C) except for regular quarterly dividends on the Company’s common stock, par value $1.00 per share (the “Common Stock”), in amounts per share that are consistent with past practice, there has been no dividend or distribution
of any kind declared, paid or made by the Company on any class of its capital stock. 
 (viii) Good Standing
of the Company. The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Connecticut and has corporate power and authority to own, lease and operate its properties and to
conduct its business as described in the General Disclosure Package and the Final Offering Memorandum and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business
and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would
not result in a Material Adverse Effect. 
 (ix) Good Standing of Subsidiaries. Each “significant
subsidiary” of the Company (as such term is defined in Rule 1-02 of Regulation S-X) (each, a “Significant Subsidiary” and, collectively, the “Significant Subsidiaries”) has been duly organized and is validly existing in good
standing under the laws of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties and to conduct its business as described in the General Disclosure Package and
the Final Offering Memorandum and is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business,
except where the failure to so qualify or to be in good standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the General Disclosure Package and the Final Offering Memorandum, all of the issued and outstanding
capital stock of each Subsidiary has been duly authorized and validly issued, is fully paid and non-assessable and is owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien,
encumbrance, claim or equity, except for the security interest granted in favor of the collateral agent under that certain Amended and Restated Security Agreement, dated as of September 20, 2010, among the Company, certain of its subsidiaries
and Bank of America, 

  
 4 








 
N.A. None of the outstanding shares of capital stock of any Subsidiary was issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The Company does not
own or control, directly or indirectly, any subsidiary (as defined in Rule 405 under the Securities Act) other than (i) the subsidiaries listed in Schedule D hereto (each a “Subsidiary” and, collectively, the
“Subsidiaries”) and (ii) subsidiaries that, if considered in the aggregate as a single subsidiary, would not constitute a Significant Subsidiary. 
 (x) Capitalization. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in the General Disclosure Package and the Final Offering Memorandum in the column
entitled “Actual” under the caption “Capitalization” (except for subsequent issuances, if any, pursuant to this Agreement, pursuant to reservations, agreements or employee benefit plans referred to in the General Disclosure
Package and the Final Offering Memorandum or pursuant to the exercise of convertible securities or options referred to in the General Disclosure Package and the Final Offering Memorandum). 

(xi) Authorization of Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

 (xii) Hedge and Warrant Confirmations. The confirmations (the “Convertible Note Hedge
Confirmations”) among the Company and the counterparties thereto (the “Note Hedge Counterparties”) relating to the OTC convertible note hedge as described in the General Disclosure Package and Final Offering Memorandum and the
confirmations (the “Warrant Transaction Confirmations”) among the Company and the counterparties thereto (the “Warrant Counterparties” and, together with the Note Hedge Counterparties, the “Counterparties”) relating to
the OTC warrant transaction described in the General Disclosure Package and Final Offering Memorandum have been duly authorized and, assuming due authorization, execution and delivery by each Counterparty, when executed and delivered by the Company,
will constitute valid and binding instruments of the Company, enforceable in accordance with their terms, subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting
creditors’ rights and to general equity principles. 
 (xiii) Authorization of the Indenture. The
Indenture has been duly authorized by the Company and, when duly executed and delivered by the Company and the Trustee, will constitute a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms,
except as the enforcement thereof may be limited by bankruptcy, insolvency (including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting enforcement of creditors’ rights
generally and except as enforcement thereof is subject to general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law). 

(xiv) Authorization of the Securities and the Common Stock. The Securities have been duly authorized and, at the
Closing Time, will have been duly executed by the Company and, when authenticated, issued and delivered in the manner provided for in the Indenture and delivered against payment of the purchase price therefor as provided in this Agreement, will
constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency (including, without limitation, all laws relating to
fraudulent transfers), reorganization, moratorium or similar laws affecting enforcement of creditors’ rights generally and except as enforcement thereof is subject to general principles of equity (regardless of whether enforcement is considered
in a proceeding in equity or at law), and will be in the form contemplated by, and entitled to the benefits of, the Indenture. The shares of Common Stock issuable upon conversion 

  
 5 








 
of the Securities have been duly authorized and reserved for issuance upon such conversion by all necessary corporate action and such shares, when issued upon such conversion, will be validly
issued and will be fully paid and non-assessable; no holder of such shares will be subject to personal liability by reason of being such a holder; and the issuance of such shares upon such conversion will not be subject to the preemptive or other
similar rights of any securityholder of the Company. 
 (xv) Description of the Securities, the Common Stock
and the Indenture. The Securities and the Indenture will conform in all material respects to the respective statements relating thereto contained in the General Disclosure Package and the Final Offering Memorandum. The Common Stock conforms to
all statements relating thereto contained or incorporated by reference in the General Disclosure Package and the Final Offering Memorandum and such description conforms to the rights set forth in the instruments defining the same. 

(xvi) Registration Rights. There are no persons with registration rights or other similar rights to have any
securities registered for sale by the Company under the 1933 Act. 
 (xvii) Absence of Violations, Defaults
and Conflicts. Neither the Company nor any of its Subsidiaries is (A) in violation of its charter, by-laws or similar organizational document, (B) in default in the performance or observance of any obligation, agreement, covenant or
condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which it or any of them may be bound or
to which any of the properties or assets of the Company or any Subsidiary is subject (collectively, “Agreements and Instruments”), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or
(C) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company
or any of its Subsidiaries or any of their respective properties, assets or operations (each, a “Governmental Entity”), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The
execution, delivery and performance of the Convertible Note Hedge Confirmations, the Warrant Transaction Confirmations and this Agreement and the consummation of the transactions contemplated herein, therein and in the General Disclosure Package and
the Final Offering Memorandum (including the issuance and sale of the Securities and the use of the proceeds from the sale of the Securities as described therein under the caption “Use of Proceeds”) and compliance by the Company with its
obligations under the Convertible Note Hedge Confirmations, the Warrant Transaction Confirmations and this Agreement have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice or
passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or any
Subsidiary pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will
such action result in any violation of the provisions of the charter, by-laws or similar organizational document of the Company or any of its Subsidiaries or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental
Entity (except for such violation of any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity that would not, singly or in the aggregate, result in a Material Adverse Effect). As used herein, a “Repayment
Event” means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a
portion of such indebtedness by the Company or any of its Subsidiaries. 

  
 6 








 (xviii) Absence of Labor Dispute. No labor dispute with the employees
of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is imminent, which would result in a Material Adverse Effect. 
 (xix) Absence of Proceedings. Except as disclosed in the General Disclosure Package and the Final Offering Memorandum, there is no action, suit, proceeding, inquiry or investigation before or
brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its Subsidiaries, which would reasonably be expected to result in a Material Adverse Effect, or which would
reasonably be expected to materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in the Convertible Note Hedge Confirmations, the Warrant Transaction Confirmations or this Agreement
or the performance by the Company of its obligations under the Convertible Note Hedge Confirmations, the Warrant Transaction Confirmations or this Agreement; and the aggregate of all pending legal or governmental proceedings to which the Company or
any such Subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in the General Disclosure Package and the Final Offering Memorandum, including ordinary routine litigation incidental to
the business, would not reasonably be expected to result in a Material Adverse Effect. 
 (xx) Absence of
Further Requirements. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations
hereunder, in connection with the offering, issuance or sale of the Securities hereunder by the Company or the consummation by the Company of the transactions contemplated by this Agreement or for the due execution, delivery and performance by the
Company of the Indenture, except such as have been already obtained. 
 (xxi) Possession of Licenses and
Permits. The Company and its Subsidiaries possess such permits, licenses, approvals, consents and other authorizations (collectively, “Governmental Licenses”) issued by the appropriate Governmental Entities necessary to conduct the
business now operated by them, except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and its Subsidiaries are in compliance with the terms and conditions of all Governmental
Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental
Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received any notice of proceedings
relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect. 

(xxii) Title to Property. The Company and its Subsidiaries have good and marketable title to all real property
owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A) are described in the
General Disclosure Package and the Final Offering Memorandum, (B) liens for Taxes or governmental assessments, charges or claims, the payment of which is not yet due or (C) do not, singly or in the aggregate, materially affect the value of
such property and do not interfere with the use made and proposed to be made 

  
 7 








 
of such property by the Company or any of its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and
under which the Company or any of its Subsidiaries holds properties described in the General Disclosure Package and the Final Offering Memorandum, are in full force and effect (except where the failure of such leases and subleases to be in full
force and effect would not, singly or in the aggregate, result in a Material Adverse Effect), and neither the Company nor any such Subsidiary has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of
the Company or any subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such subsidiary to the continued possession of the leased or subleased premises under any such lease or
sublease. 
 (xxiii) Possession of Intellectual Property. The Company and its Subsidiaries own or possess,
or can acquire on reasonable terms, adequate patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures),
trademarks, service marks, trade names or other intellectual property (collectively, “Intellectual Property”) necessary to carry on the business now operated by them, and neither the Company nor any of its Subsidiaries has received any
notice or is otherwise aware of any infringement of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or circumstances which would render any Intellectual Property invalid or inadequate to protect
the interest of the Company or any of its Subsidiaries therein, and which infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or inadequacy, singly or in the aggregate, would result in a Material
Adverse Effect. 
 (xxiv) Environmental Laws. Except as described in the General Disclosure Package and
the Final Offering Memorandum or would not, singly or in the aggregate, result in a Material Adverse Effect, (A) neither the Company nor any of its Subsidiaries is in violation of any federal, state, local or foreign statute, law, rule,
regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the
environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals,
pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”) (except for such violation of Environmental Laws that would not, singly or in the aggregate, result in a Material Adverse
Effect) (B) the Company and its Subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements (except where the lack of such permit, authorization
or approval or non-compliance would not, singly or in the aggregate, result in a Material Adverse Effect), (C) there are no pending or, to the Company’s knowledge, threatened administrative, regulatory or judicial actions, suits, demands,
demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (D) there are no events or circumstances that would
reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any of its subsidiaries relating to Hazardous
Materials or any Environmental Laws that would reasonably be expected to result in a Material Adverse Effect. 

  
 8 








 (xxv) Accounting Controls and Disclosure Controls. The Company and
each of its Subsidiaries maintain effective internal control over financial reporting (as defined under Rule 13-a15 and 15d-15 under the 1934 Act Regulations) and a system of internal accounting controls sufficient to provide reasonable assurances
that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; and (D) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as described in the General Disclosure Package and the Final Offering Memorandum, since the end of the Company’s most recent audited fiscal year, there has been
(1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (2) no change in the Company’s internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company and each of its Subsidiaries maintain an effective system of disclosure controls and procedures (as defined in Rule 13a-15 and Rule
15d-15 under the 1934 Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time
periods specified in the Commission’s rules and forms, and is accumulated and communicated to the Company’s management, including its principal executive officer or officers and principal financial officer or officers, as appropriate, to
allow timely decisions regarding disclosure. 
 (xxvi) Compliance with the Sarbanes-Oxley Act. There is
and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations
promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications. 
 (xxvii) Payment of Taxes. All United States federal income tax returns of the Company and its Subsidiaries required by law to be filed have been filed and all taxes shown by such returns or
otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have been provided. No assessment has been made against the Company in
respect of United States federal income tax returns of the Company through the fiscal year ended December 31, 2009. The Company and its subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to
applicable foreign, state, local or other law except insofar as the failure to file such returns would not result in a Material Adverse Effect, and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company
and its subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company. The charges, accruals and reserves on the books of the Company in respect of any income
and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in
a Material Adverse Effect. 
 (xxviii) Insurance. The Company and its subsidiaries carry or are entitled
to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as is sufficient for the Company’s business as now conducted, and all such insurance is in full force and effect. To the
Company’s knowledge, neither the Company nor any of its Subsidiaries will be unable (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable coverage from similar institutions as may be
necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. 

  
 9 








 (xxix) Investment Company Act. The Company is not required, and upon
the issuance and sale of the Securities as herein contemplated and the application of the net proceeds therefrom as described in the General Disclosure Package and the Final Offering Memorandum will not be required, to register as an
“investment company” under the Investment Company Act of 1940, as amended (the “1940 Act”). 

(xxx) Absence of Manipulation. Neither the Company nor any affiliate controlled by the Company has taken, nor will
the Company or any affiliate of the Company take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which has constitutes, the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of the Securities. 
 (xxxi) Foreign Corrupt Practices Act. None
of the Company, any of its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate controlled by the Company or other person acting on behalf of the Company or any of its subsidiaries (excluding the
Initial Purchasers, in their capacity as such, as to which no representation or warranty is made) is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of
1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise
to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political
party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates controlled by the Company have conducted their businesses in compliance with
the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. 

(xxxii) Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at
all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any
Governmental Entity involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. 

(xxxiii) OFAC. None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any director,
officer, agent, employee, affiliate controlled by the Company or other person acting on behalf of the Company or any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S.
Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any of its subsidiaries, joint venture partners
or other person, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. 

  
 10 









 (xxxiv) Statistical and Market-Related Data. Any statistical and
market-related data included in the General Disclosure Package or the Final Offering Memorandum are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate and, to the extent required, the
Company has obtained the written consent to the use of such data from such sources. 
 (b) Officer’s Certificates.
Any certificate signed by any officer of the Company or any of its subsidiaries delivered to the Representatives or to counsel for the Initial Purchasers shall be deemed a representation and warranty by the Company to each Initial Purchaser as to
the matters covered thereby. 
 SECTION 2. Sale and Delivery to Initial Purchasers; Closing. 

(a) Initial Securities. On the basis of the representations and warranties herein contained and subject to the terms and
conditions herein set forth, the Company agrees to sell to each Initial Purchaser, severally and not jointly, and each Initial Purchaser, severally and not jointly, agrees to purchase from the Company, at the price set forth in Schedule A, the
aggregate principal amount of Initial Securities set forth in Schedule A, plus any additional principal amount of Initial Securities which such Initial Purchaser may become obligated to purchase pursuant to the provisions of Section 11 hereof,
subject to such adjustments as Merrill Lynch in its discretion shall make to ensure that any sales or purchases are in authorized denominations. 
 (b) Option Securities. In addition, on the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company hereby grants an option
to the Initial Purchasers, severally and not jointly, to purchase the Option Securities, at the price set forth in Schedule A. The option hereby granted will expire 30 days after the date hereof and may be exercised in whole or in part from
time to time only for the purpose of covering overallotments made in connection with the offering and distribution of the Initial Securities upon notice by the Representatives to the Company setting forth the amount of Option Securities as to which
the several Initial Purchasers are then exercising the option and the time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a “Date of Delivery”) shall be determined by the Representatives,
but shall not be later than seven full business days after the exercise of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities, each of the Initial Purchasers, acting
severally and not jointly, will purchase that proportion of the total principal amount of Option Securities then being purchased which the number of Initial Securities set forth in Schedule A opposite the name of such Initial Purchaser bears to the
total principal amount of Initial Securities, subject in each case to such adjustments as Merrill Lynch in its discretion shall make to ensure that any sales or purchases are in authorized denominations. 

(c) Payment. Payment of the purchase price for, and delivery of certificates for, the Initial Securities shall be made at the
offices of Shearman & Sterling LLP, 599 Lexington Avenue, New York, New York 10022, or at such other place as shall be agreed upon by the Representatives and the Company, at 9:00 A.M. (New York City time) on the third (fourth, if the
pricing occurs after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section 11), or such other time not later than ten business days after such date as
shall be agreed upon by the Representatives and the Company (such time and date of payment and delivery being herein called “Closing Time”). 
 In addition, in the event that any or all of the Option Securities are purchased by the Initial Purchasers, payment of the purchase price for, and delivery of certificates for, such Option Securities
shall be made at the above-mentioned offices, or at such other place as shall be agreed upon by the Representatives and the Company, on each Date of Delivery as specified in the notice from the Representatives to the Company. 

  
 11 









 Payment shall be made to the Company by wire transfer of immediately available funds to a
bank account designated by the Company, against delivery to the Representatives for the respective accounts of the Initial Purchasers of certificates for the Securities to be purchased by them. It is understood that each Initial Purchaser has
authorized the Representatives, for its account, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed to purchase. Merrill Lynch, individually
and not as representative of the Initial Purchasers, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Initial Purchaser whose funds have not
been received by the Closing Time or the relevant Date of Delivery, as the case may be, but such payment shall not relieve such Initial Purchaser from its obligations hereunder. 

(d) Denominations; Registration. Certificates for the Initial Securities and the Option Securities, if any, shall be in such
denominations ($1,000 or integral multiples thereof) and registered in such names as the Representatives may request in writing at least one full business day before the Closing Time or the relevant Date of Delivery, as the case may be. The Initial
Securities and the Option Securities, if any, will be made available for examination and packaging by the Representatives in The City of New York not later than 10:00 A.M. (New York City time) on the business day prior to the Closing Time or
the relevant Date of Delivery, as the case may be. 
 SECTION 3. Covenants of the Company. The Company covenants with
each Initial Purchaser as follows: 
 (a) Delivery of Offering Memorandum. The Company has delivered to each Initial
Purchaser, without charge, as many copies of the Preliminary Offering Memorandum (as amended or supplemented) thereto and documents incorporated by reference therein as such Initial Purchaser reasonably requested, and the Company hereby consents to
the use of such copies in connection with the transactions contemplated by this Agreement. The Company will furnish to each Initial Purchaser, without charge, such number of copies of the Final Offering Memorandum thereto and documents incorporated
by reference therein as such Initial Purchaser may reasonably request. 
 (b) Notice and Effect of Material Events. If at
any time prior to the completion of resales of the Securities by the Initial Purchasers, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Initial Purchasers or for the Company, to
amend or supplement the General Disclosure Package or the Final Offering Memorandum in order that the General Disclosure Package or the Final Offering Memorandum, as the case may be, will not include any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a Subsequent Purchaser, the Company will promptly (A) give the Representatives
notice of such event and (B) prepare any amendment or supplement as may be necessary to correct such statement or omission and, a reasonable amount of time prior to any proposed use or distribution, furnish the Representatives with copies of
any such amendment or supplement; provided that the Company shall not use or distribute any such amendment or supplement to which the Representatives or counsel for the Initial Purchasers shall object. The Company will furnish to the Initial
Purchasers such number of copies of such amendment or supplement as the Initial Purchasers may reasonably request. 
 (c)
Reporting Requirements. Until the completion of resales of the Securities by the Initial Purchasers, the Company will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the
1934 Act and the 1934 Act Regulations. The Company 

  
 12 









 
has given the Representatives notice of any filings made pursuant to the 1934 Act or 1934 Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representatives
notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representatives with copies of any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and
will not file or use any such document to which the Representatives or counsel for the Initial Purchasers shall reasonably object. 
 (d) Blue Sky Qualifications. The Company will use its best efforts, in cooperation with the Initial Purchasers, to qualify the Securities for offering and sale under the applicable securities laws
of such states and other jurisdictions (domestic or foreign) as the Representatives may designate and to maintain such qualifications in effect so long as required to complete the distribution of the Securities; provided, however, that the Company
shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing
business in any jurisdiction in which it is not otherwise so subject. 
 (e) Use of Proceeds. The Company will use the
net proceeds received by it from the sale of the Securities in the manner specified in the General Disclosure Package and the Final Offering Memorandum under “Use of Proceeds.” 

(f) DTCC. The Company will cooperate with the Initial Purchasers and use its best efforts to permit the offered Securities to be
eligible for clearance and settlement through the facilities of The Depository Trust & Clearing Corporation (“DTCC”). 
 (g) Listing. The Company will use its best efforts to effect and maintain the listing of the Common Stock issuable upon conversion of the Securities on the Nasdaq Global Market or New York Stock
Exchange. 
 (h) Restriction on Sale of Securities. During a period of 90 days from the date of the Final Offering
Memorandum, the Company will not, without the prior written consent of Merrill Lynch, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file any registration statement under the 1933 Act with respect
to any of the foregoing or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or
transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (A) the Securities to be sold hereunder,
(B) any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof and referred to in the General Disclosure Package and the Final Offering Memorandum,
(C) any shares of Common Stock issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company referred to in the General Disclosure Package and the Final Offering Memorandum or as inducement grants
pursuant to the rules of the NASDAQ Stock Market, provided such grants are subject to restrictions substantially similar to those set forth above (D) any shares of Common Stock issued pursuant to any non-employee director stock plan or dividend
reinvestment plan referred to in the General Disclosure Package and the Final Offering Memorandum, (E) the filing of any registration statement on Form S-8 to register shares of common stock reserved for issuance under the Company’s
existing employee benefit plans or (F) during the last 60 days of such 90 day period, the issuance of shares of Common Stock which the Company may issue or agree to issue in connection with the acquisition of one or more businesses,
products or technologies (whether by means of merger, stock purchase or asset 

  
 13 









 
purchase), provided that such shares of common stock are subject to restrictions substantially similar to those set forth above and provided, further, that the aggregate number of
shares of Common Stock issued or agreed to be issued in such transactions in the aggregate shall not exceed five percent (5%) of the Company’s outstanding Common Stock as of the Closing Time. 

SECTION 4. Payment of Expenses. 
 (a) Expenses. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including (i) preparation, issuance and delivery of the
Securities to the Initial Purchasers and the Common Stock issuable upon conversion thereof and any charges of DTCC in connection therewith, (ii) the fees and disbursements of the Company’s counsel, accountants and other advisors,
(iii) the qualification of the Securities under securities laws in accordance with the provisions of Section 3(d) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Initial Purchasers in connection
therewith and in connection with the preparation of the Blue Sky Survey and any supplement thereto, (iv) the preparation, printing and delivery to the Initial Purchasers of copies of each Preliminary Offering Memorandum, any Issuer Written
Information, the Final Term Sheet and the Final Offering Memorandum and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Initial Purchasers to investors, (v) all fees and
expenses of the Trustee and any expenses of any transfer agent or registrar for the Securities or the Common Stock issuable upon conversion of the Securities, (vi) the costs and expenses of the Company relating to investor presentations on any
“road show” undertaken in connection with the marketing of the Securities, including without limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection
with the road show presentations, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of aircraft and other transportation chartered in connection with the road show, (vii) the
fees and expenses incurred in connection with the listing of the Common Stock issuable upon conversion of the Securities on the Nasdaq Global Market and (viii) the costs and expenses (including, without limitation, any damages or other amounts
payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made by the Initial Purchasers caused by a breach of the representation contained in the first sentence of
Section 1(a)(iii). 
 (b) Termination of Agreement. If this Agreement is terminated by the Representatives in
accordance with the provisions of Section 5, Section 10(a)(i) or (iii) or Section 11 hereof, the Company shall reimburse the Initial Purchasers for all of their reasonable out-of-pocket expenses, including the reasonable fees and
disbursements of counsel for the Initial Purchasers. In the case of termination by the Representatives in accordance with the provisions of Section 11, the Company shall have no obligation to reimburse a defaulting Initial Purchaser pursuant to
this Section 4(b). 
 SECTION 5. Conditions of Initial Purchasers’ Obligations. The obligations of the several
Initial Purchasers hereunder are subject to the accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its subsidiaries, to the performance by the Company of its
covenants and other obligations hereunder, and to the following further conditions: 
 (a) Opinion of Counsel for
Company. At the Closing Time, the Representatives shall have received an opinion, dated the Closing Time, of Crowell & Moring LLP, counsel for the Company, in form and substance satisfactory to counsel for the Initial Purchasers,
together with signed or reproduced copies of such letter for each of the other Initial Purchasers to the effect set forth in Exhibit A - 1 hereto. In giving such opinion, such counsel may rely, as to all matters governed by the laws of jurisdictions
other than the law of the State of New York and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representatives. 

  
 14 









 (b) Opinion of Local Counsel for Company. At the Closing Time, the Representatives
shall have received an opinion, dated the Closing Time, of Murtha Cullina LLP, counsel for the Company, in form and substance satisfactory to counsel for the Initial Purchasers, together with signed or reproduced copies of such letter for each of
the other Initial Purchasers to the effect set forth in Exhibit A - 2 hereto. In giving such opinion, such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of Connecticut and the federal
securities laws of the United States, upon the opinions of counsel satisfactory to the Representatives. 
 (c) Opinion of
Chief Legal Counsel of Company. At the Closing Time, the Representatives shall have received an opinion, dated the Closing Time, of Candace Clark, Senior Vice President and Chief Legal Counsel of the Company, in form and substance satisfactory
to counsel for the Initial Purchasers, together with signed or reproduced copies of such letter for each of the other Initial Purchasers to the effect set forth in Exhibit A - 3 hereto. 

(d) Opinion of Counsel for Initial Purchasers. At the Closing Time, the Representatives shall have received an opinion, dated the
Closing Time, of Shearman & Sterling LLP, counsel for the Initial Purchasers, together with signed or reproduced copies of such letter for each of the other Initial Purchasers in form and substance satisfactory to the Representatives. In
giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the
Representatives. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and its subsidiaries and
certificates of public officials. 
 (e) Officers’ Certificate. At the Closing Time, there shall not have been,
since the date hereof or since the respective dates as of which information is given in the General Disclosure Package or the Final Offering Memorandum, any material adverse change in the condition, financial or otherwise, or in the earnings,
business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, and the Representatives shall have received a certificate of the Chief Executive
Officer/President of the Company and of the chief financial or chief accounting officer of the Company, dated the Closing Time, to the effect that (i) there has been no such material adverse change, (ii) the representations and warranties
of the Company in this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time and (iii) the Company has complied with all agreements and satisfied all conditions on its part to be
performed or satisfied at or prior to the Closing Time. 
 (f) Accountant’s Comfort Letter. At the time of the
execution of this Agreement, the Representatives shall have received from KPMG LLP a letter, dated such date, in form and substance satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other
Initial Purchasers containing statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in the
Offering Memorandum. 
 (g) Bring-down Comfort Letter. At the Closing Time, the Representatives shall have received from
KPMG LLP a letter, dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (f) of this Section, except that the specified date referred to shall be a date not more than
three business days prior to the Closing Time. 

  
 15 









 (h) Approval of Listing. At the Closing Time, the Common Stock issuable upon
conversion of the Securities shall have been approved for listing on the Nasdaq Global Market, subject only to official notice of issuance. 
 (i) Lock-up Agreements. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of Exhibit B hereto signed by the persons listed on
Schedule E hereto. 
 (j) Maintenance of Rating. Since the execution of this Agreement, there shall not have been any
decrease in or withdrawal of the rating of any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” (as such term is defined in Section 3(a)(62) of the 1934 Act) or any
notice given of any intended or potential decrease in or withdrawal of any such rating or of a possible change in any such rating that does not indicate the direction of the possible change. 

(k) Execution and Delivery of Certain Transaction Documents. At or prior to the Closing Time, the Company shall have executed and
delivered the Convertible Note Hedge Confirmations and the Warrant Transaction Confirmations, each in a form satisfactory to the Representatives. 
 (l) Conditions to Purchase of Option Securities. In the event that the Initial Purchasers exercise their option provided in Section 2(b) hereof to purchase all or any portion of the Option
Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company and any of its subsidiaries hereunder shall be true and correct as of each Date of Delivery and, at the
relevant Date of Delivery, the Representatives shall have received: 
 (i) Officers’ Certificate. A
certificate, dated such Date of Delivery, of the President or a Vice President of the Company and of the chief financial or chief accounting officer of the Company confirming that the certificate delivered at the Closing Time pursuant to
Section 5(d) hereof remains true and correct as of such Date of Delivery. 
 (ii) Opinion of Counsel for
Company. If requested by the Representatives, an opinion of Crowell & Moring LLP, counsel for the Company, in form and substance satisfactory to counsel for the Initial Purchasers, dated such Date of Delivery, relating to the Option
Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section 5(a) hereof. 
 (iii) Opinion of Local Counsel for Company. If requested by the Representatives, an opinion of Murtha Cullina LLP, counsel for the Company, in form and substance satisfactory to counsel for the
Initial Purchasers, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section 5(b) hereof. 

(iv) Opinion of Chief Legal Counsel of Company. If requested by the Representatives, an opinion of Candace Clark,
Senior Vice President and Chief Legal Counsel of the Company, in form and substance satisfactory to counsel for the Initial Purchasers, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and
otherwise to the same effect as the opinion required by Section 5(c) hereof. 
 (v) Opinion of Counsel
for Initial Purchasers. If requested by the Representatives, an opinion of Shearman & Sterling LLP, counsel for the Initial Purchasers, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of
Delivery and otherwise to the same effect as the opinion required by Section 5(d) hereof. 

  
 16 









 (vi) Bring-down Comfort Letter. If requested by the Representatives,
a letter from KPMG LLP, in form and substance satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to Section 5(g) hereof,
except that the “specified date” in the letter furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery. 
 (m) Additional Documents. At the Closing Time and at each Date of Delivery (if any), counsel for the Initial Purchasers shall have been furnished with such documents and opinions as they may
require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions,
herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be satisfactory in form and substance to the Representatives and counsel for the Initial Purchasers.

 (n) Termination of Agreement. If any condition specified in this Section shall not have been fulfilled when and as
required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the obligations of the several Initial Purchasers to purchase the relevant Option
Securities, may be terminated by the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such termination shall be without liability of any party to any other party
except as provided in Section 4 and except that Sections 1, 7, 8, 9, 14, 15 and 16 shall survive any such termination and remain in full force and effect. 
 SECTION 6. Subsequent Offers and Resales of the Securities. 
 (a) Offer
and Sale Procedures. Each of the Initial Purchasers and the Company hereby establish and agree to observe the following procedures in connection with the offer and sale of the Securities: 

(i) Offers and Sales. Offers and sales of the Securities shall be made to such persons and in such manner as is
contemplated by the Offering Memorandum. Each Initial Purchaser severally agrees that it will not offer, sell or deliver any of the Securities in any jurisdiction outside the United States except under circumstances that will result in compliance
with the applicable laws thereof, and that it will take at its own expense whatever action is required to permit its purchase and resale of the Securities in such jurisdictions. The Company has not entered into any contractual arrangement, other
than this Agreement, with respect to the offering and sale of the Securities or the Common Stock issuable upon conversion of the Securities and the Company will not enter into any such arrangement except as contemplated thereby. 

(ii) No General Solicitation. No general solicitation or general advertising (within the meaning of
Rule 502(c) under the 1933 Act Regulations) will be used in the United States in connection with the offering or sale of the Securities. 
 (iii) Legends. Each of the Securities will bear, to the extent applicable, the legend contained in “Notice to Investors” in the General Disclosure Package and the Final Offering
Memorandum for the time period and upon the other terms stated therein. 

  
 17 









 (iv) Minimum Principal Amount. No sale of the Securities to any one
Subsequent Purchaser will be for less than U.S. $1,000 principal amount and no Security will be issued in a smaller principal amount. If the Subsequent Purchaser is a non-bank fiduciary acting on behalf of others, each person for whom it is acting
must purchase at least U.S. $1,000 principal amount of the Securities. 
 (b) Covenants of the Company. The Company
covenants with each Initial Purchaser as follows: 
 (i) Integration. The Company agrees that it will not
and will cause its affiliates controlled by the Company not to, directly or indirectly, solicit any offer to buy, sell or make any offer or sale of, or otherwise negotiate in respect of, securities of the Company of any class if, as a result of the
doctrine of “integration” referred to in Rule 502 under the 1933 Act Regulations, such offer or sale would render invalid (for the purpose of (i) the sale of the offered Securities by the Company to the Initial Purchasers,
(ii) the resale of the offered Securities by the Initial Purchasers to Subsequent Purchasers or (iii) the resale of the offered Securities by such Subsequent Purchasers to others) the exemption from the registration requirements of the
1933 Act provided by Section 4(2) thereof or by Rule 144A thereunder or otherwise. 
 (ii) Rule
144A Information. The Company agrees that, in order to render the offered Securities eligible for resale pursuant to Rule 144A, while any of the offered Securities remain outstanding, it will make available, upon request, to any holder of
offered Securities or prospective purchasers of Securities the information specified in Rule 144A(d)(4), unless the Company furnishes information to the Commission pursuant to Section 13 or 15(d) of the 1934 Act. 

(iii) Restriction on Repurchases. Until the expiration of one year after the original issuance of the offered
Securities, the Company will not, and will cause its affiliates controlled by the Company not to, resell any offered Securities which are “restricted securities” (as such term is defined under Rule 144(a)(3)), whether as beneficial
owner or otherwise (except as agent acting as a securities broker on behalf of and for the account of customers in the ordinary course of business in unsolicited broker’s transactions). 

(c) Representations, Warranties and Agreements of the Initial Purchasers. Each Initial Purchaser severally and not jointly
represents and warrants to, and agrees with, the Company that it is a “Qualified Institutional Buyer” within the meaning of Rule 144A under the 1933 Act Regulations and an “accredited investor” within the meaning of
Rule 501(a) under the 1933 Act Regulations. Each Initial Purchaser understands that the offered Securities have not been and will not be registered under the 1933 Act and may not be offered or sold within the United States except
pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act. Each Initial Purchaser severally represents and agrees that it has not offered or sold, and will not offer or sell, any offered
Securities constituting part of its allotment within the United States except in accordance with Rule 144A or another applicable exemption from the registration requirements of the 1933 Act. Accordingly, neither it nor any person acting on
its behalf has made or will make offers or sales of the Securities in the United States by means of any form of general solicitation or general advertising (within the meaning of Regulation D) in the United States. Each Initial Purchaser will take
reasonable steps to inform, and cause each of its affiliates (as such term is defined in Rule 501(b) under the 1933 Act Regulations (each, an “Affiliate”)) to take reasonable steps to inform, persons acquiring Securities from such Initial
Purchaser or Affiliate, as the case may be, in the United States that the Securities (A) have not been and will not be registered under the 1933 Act, (B) are being sold to them without registration under the 1933 Act in reliance
on Rule 144A or in accordance with another exemption from registration under the 1933 Act, as the case may be, and (C) may not be offered, sold or otherwise transferred except (1) to the Company,


  
 18 









 
(2) outside the United States in accordance with Regulation S or (3) inside the United States in accordance with (x) Rule 144A to a person whom the seller reasonably
believes is a Qualified Institutional Buyer that is purchasing such Securities for its own account or for the account of a Qualified Institutional Buyer to whom notice is given that the offer, sale or transfer is being made in reliance on
Rule 144A or (y) pursuant to another available exemption from registration under the 1933 Act. 
 SECTION 7.
Indemnification. 
 (a) Indemnification of Initial Purchasers. The Company agrees to indemnify and hold harmless
each Initial Purchaser, its Affiliates, its selling agents and each person, if any, who controls any Initial Purchaser within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows: 

(i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue
statement or alleged untrue statement of a material fact included in any Preliminary Offering Memorandum, the Final Offering Memorandum, the information contained in the Final Term Sheet, any Issuer Written Information or any other written
information used by or on behalf of the Company that has been previously reviewed and approved for distribution by the Company in connection with the offer or sale of the Securities (or any amendment or supplement to the foregoing) or the omission
or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; 

(ii) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the
aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged
untrue statement or omission; provided that (subject to Section 7(d) below) any such settlement is effected with the written consent of the Company; 
 (iii) against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by Merrill Lynch), reasonably incurred in investigating, preparing or defending against
any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent
that any such expense is not paid under (i) or (ii) above; 
 provided, however, that this indemnity agreement shall not apply to any
loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in any Preliminary Offering Memorandum, the Final Offering Memorandum or the information contained
in the Final Term Sheet (or any amendment or supplement to the foregoing) in reliance upon and in conformity with the Initial Purchaser Information. 
 (b) Indemnification of Company, Directors and Officers. Each Initial Purchaser severally and not jointly agrees to indemnify and hold harmless the Company, its directors, its officers and each
person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection
(a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in any Preliminary Offering Memorandum, the Final Offering Memorandum or the information contained in the
Final Term Sheet (or any amendment or supplement to the foregoing) in reliance upon and in conformity with the Initial Purchaser Information. 

  
 19 









 (c) Actions against Parties; Notification. Each indemnified party shall give notice
as promptly as reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from
any liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. In the case of parties
indemnified pursuant to Section 7(a) above, counsel to the indemnified parties shall be selected by Merrill Lynch, and, in the case of parties indemnified pursuant to Section 7(b) above, counsel to the indemnified parties shall be selected
by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the
indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action
or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or
consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be
sought under this Section 7 or Section 8 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified
party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

 (d) Settlement without Consent if Failure to Reimburse. If at any time an indemnified party shall have requested an
indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 7(a)(ii) effected without its written
consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days
prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. 

SECTION 8. Contribution. If the indemnification provided for in Section 7 hereof is for any reason unavailable to or
insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims,
damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Initial Purchasers, on the other hand, from the
offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause
(i) above but also the relative fault of the Company, on the one hand, and of the Initial Purchasers, on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as
well as any other relevant equitable considerations. 
 The relative benefits received by the Company, on the one hand, and the
Initial Purchasers, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to
this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Initial Purchasers, on the other hand, bear to the aggregate initial offering price of the Securities as set
forth on the cover of the Final Offering Memorandum. 

  
 20 









 The relative fault of the Company, on the one hand, and the Initial Purchasers, on the other
hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or by the
Initial Purchasers and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 The Company and the Initial Purchasers agree that it would not be just and equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Initial Purchasers
were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section 8. The aggregate amount of losses, liabilities, claims, damages and
expenses incurred by an indemnified party and referred to above in this Section 8 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any
litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission. 

Notwithstanding the provisions of this Section 8, no Initial Purchaser shall be required to contribute any amount in excess of the
amount by which the total price at which the Securities purchased and sold by it hereunder exceeds the amount of any damages which such Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or
omission or alleged omission. 
 No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 
 For
purposes of this Section 8, each person, if any, who controls an Initial Purchaser within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Initial Purchaser’s Affiliates and selling agents shall
have the same rights to contribution as such Initial Purchaser, and each director of the Company, each officer of the Company, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20
of the 1934 Act shall have the same rights to contribution as the Company. The Initial Purchasers’ respective obligations to contribute pursuant to this Section 8 are several in proportion to the aggregate principal amount of Initial
Securities set forth opposite their respective names in Schedule A hereto and not joint. 
 SECTION 9. Representations,
Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain operative and in
full force and effect regardless of (i) any investigation made by or on behalf of any Initial Purchaser or its Affiliates or selling agents, any person controlling any Initial Purchaser, its officers or directors or any person controlling the
Company and (ii) delivery of and payment for the Securities. 
 SECTION 10. Termination of Agreement. 

(a) Termination. The Representatives, in their absolute discretion, may terminate this Agreement without liability to the Company,
by notice to the Company, at any time at or prior to the Closing Time (i) if there has been, since the time of execution of this Agreement or since the respective dates as of which information is given in the General Disclosure Package or the
Final Offering Memorandum, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in
the ordinary course of business, or (ii) if there has occurred any material adverse 

  
 21 









 
change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or
development involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives, impracticable or inadvisable to
proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii) if trading in any securities of the Company has been suspended or materially limited by the Commission or the Nasdaq Global Market, or
(iv) if trading generally on the New York Stock Exchange or in the Nasdaq Global Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any
of said exchanges or by order of the Commission, the Financial Industry Regulatory Authority (FINRA) or any other governmental authority, or (v) a material disruption has occurred in commercial banking or securities settlement or clearance
services in the United States, or (vi) if a banking moratorium has been declared by either Federal or New York authorities. 
 (b) Liabilities. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other party except as provided in Section 4 hereof,
and provided further that Sections 1, 6(c), 7, 8, 9, 14, 15 and 16 shall survive such termination and remain in full force and effect. 
 SECTION 11. Default by One or More of the Initial Purchasers. If one or more of the Initial Purchasers shall fail at the Closing Time or a Date of Delivery to purchase the Securities which it or
they are obligated to purchase under this Agreement (the “Defaulted Securities”), the Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting Initial Purchasers, or
any other initial purchasers, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements
within such 24-hour period, then: 
 (i) if the number of Defaulted Securities does not exceed 10% of the
aggregate principal amount of the Securities to be purchased on such date, each of the non-defaulting Initial Purchasers shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective
underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Initial Purchasers, or 
 (ii) if the number of Defaulted Securities exceeds 10% of the aggregate principal amount of the Securities to be purchased on such date, this Agreement or, with respect to any Date of Delivery which
occurs after the Closing Time, the obligation of the Initial Purchasers to purchase, and the Company to sell, the Option Securities to be purchased and sold on such Date of Delivery, shall terminate without liability on the part of any
non-defaulting Initial Purchaser. 
 No action taken pursuant to this Section shall relieve any defaulting Initial Purchaser
from liability in respect of its default. 
 In the event of any such default which does not result in a termination of this
Agreement or, in the case of a Date of Delivery which is after the Closing Time, which does not result in a termination of the obligation of the Initial Purchasers to purchase and the Company to sell the relevant Option Securities, as the case may
be, either the (i) Representatives or (ii) the Company shall have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the
General Disclosure Package or the Final Offering Memorandum or in any other documents or arrangements. As used herein, the term “Initial Purchaser” includes any person substituted for an Initial Purchaser under this Section 11.


  
 22 









 SECTION 12. Notices. All notices and other communications hereunder shall be in
writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Initial Purchasers shall be directed to Merrill Lynch at One Bryant Park, New York, New York 10036, attention of
Syndicate Department, with a copy to ECM Legal; notices to the Company shall be directed to it at 1332 Blue Hills Avenue, Bloomfield, Connecticut 06002, attention of Robert Starr, Vice President and Treasurer. 

SECTION 13. No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the
Securities pursuant to this Agreement, including the determination of the initial offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and
the several Initial Purchasers, on the other hand, (b) in connection with the offering of the Securities and the process leading thereto, each Initial Purchaser is and has been acting solely as a principal and is not the agent or fiduciary of
the Company, any of its subsidiaries or their respective stockholders, creditors, employees or any other party, (c) no Initial Purchaser has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to
the offering of the Securities or the process leading thereto (irrespective of whether such Initial Purchaser has advised or is currently advising the Company or any of its subsidiaries on other matters) and no Initial Purchaser has any obligation
to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d) the Initial Purchasers and their respective affiliates may be engaged in a broad range of transactions that involve
interests that differ from those of the Company and (e) the Initial Purchasers have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective
legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. 
 SECTION 14. Parties. This
Agreement shall each inure to the benefit of and be binding upon the Initial Purchasers and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or
corporation, other than the Initial Purchasers and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections 7 and 8 and their heirs and legal representatives, any legal or
equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Initial Purchasers and the
Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Initial
Purchaser shall be deemed to be a successor by reason merely of such purchase. 
 SECTION 15. Trial by Jury. The Company
(on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Initial Purchasers hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. 
 SECTION
16. GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW
PROVISIONS. 
 SECTION 17. TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN,
SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. 

  
 23 









 SECTION 18. Partial Unenforceability. The invalidity or unenforceability of any
Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be
invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. 
 SECTION 19. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and
the same Agreement. 
 SECTION 20. Effect of Headings. The Section headings herein are for convenience only and shall not
affect the construction hereof. 

  
 24 









 If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Initial Purchasers and the Company in accordance with its terms. 

 

					
	Very truly yours,
	
	KAMAN CORPORATION
		
	By	 	/s/ William C. Denninger
		 	Name:	 	William C. Denninger
		 	Title:	 	 Senior Vice President &
 Chief Financial Officer



  

			
	 CONFIRMED AND ACCEPTED,
 as of the date first above written:

	
	 MERRILL LYNCH, PIERCE, FENNER &
SMITH INCORPORATED

		
	By	 	/s/ David Iwan
		 	Authorized Signatory
	
	RBS SECURITIES INC.
		
	By	 	/s/ Robert Hammer
		 	Authorized Signatory
		
		 	     Robert Hammer
		
		 	     Head of Equity and Structured Retail

 For themselves and as Representatives of the other Initial Purchasers named in Schedule A hereto. 

  
 25 









 SCHEDULE A 
 The initial offering price of the Securities shall be 100% of the principal amount thereof, plus accrued interest, if any, from the date of issuance. 

The purchase price to be paid by the Initial Purchasers for the Securities shall be 97% of the principal amount thereof. 

The interest rate on the Securities shall be 3.25% per annum. 
  

					
	 Name of Initial Purchaser
	  	Principal
Amount of
Securities	 
	 Merrill Lynch, Pierce, Fenner & Smith Incorporated
	  	$	65,000,000	  
	 RBS Securities Inc.
	  	$	20,000,000	  
	 J.P. Morgan Securities LLC
	  	$	7,000,000	  
	 Stifel, Nicolaus & Company, Incorporated
	  	$	2,000,000	  
	 CJS Securities, Inc.
	  	$	2,000,000	  
	 Sidoti & Company, LLC
	  	$	2,000,000	  
	 Stephens Inc.
	  	$	2,000,000	  
		  	 	 	 
	 Total
	  	$	100,000,000	 
		  	 	 	 


  
 Sch A - 1









 SCHEDULE B 
 Final Term Sheet 
 Pricing term sheet dated November 15, 2010 

to Preliminary Offering Memorandum dated November 15, 2010 
 (the “Preliminary Offering Memorandum”) 
 Kaman Corporation

 $100,000,000 
 3.25% Convertible Senior Notes due 2017 
 The information in this pricing term sheet
relates only to the offering of $100,000,000 aggregate principal amount of 3.25% Convertible Senior Notes due 2017 by Kaman Corporation and should be read together with the Preliminary Offering Memorandum and supersedes the information in the
Preliminary Offering Memorandum to the extent inconsistent with the information in the Preliminary Offering Memorandum. Terms used in this pricing term sheet but not defined herein have the respective meanings given to them in the Preliminary
Offering Memorandum. 
  

			
	Issuer:	  	Kaman Corporation.
		
	Ticker/Exchange for Common Stock:	  	KAMN/NASDAQ Global Select Market (“NASDAQ”).
		
	Title of Securities:	  	3.25% Convertible Senior Notes due 2017.
		
	Aggregate Principal Amount Offered:	  	$100,000,000 aggregate principal amount of notes (excluding the initial purchasers’ option to purchase up to $15,000,000 of additional aggregate principal amount of notes
solely to cover overallotments, if any)
		
	Net Proceeds of the Offering:	  	Approximately $96.3 million (or approximately $110.9 million if the initial purchasers exercise their overallotment option to purchase additional notes in full), after
deducting the initial purchasers’ discounts and commissions and estimated offering expenses of $0.7 million payable by the Issuer.
		
	Convertible Note Hedge and Warrant Transactions:	  	The cost of the convertible note hedge transactions, after being partially offset by the proceeds from the sale of the warrants, will be approximately $9.9 million. If the
over-allotment option is exercised, we will use a portion of the additional net proceeds (together with the proceeds from the sale of additional warrants) to increase the size of the convertible note hedge transactions. The exercise price of the
warrant transactions represents a 70% premium over the Closing Stock Price.
		
	Maturity:	  	The notes will mature on November 15, 2017, unless earlier purchased by the Issuer or converted.


  
 Sch
C - 1 









			
		
	Annual Interest Rate:	  	3.25% per annum.
		
	Interest Payment Dates:	  	Interest will accrue from November 19, 2010, and will be payable semiannually in arrears on May 15 and November 15 of each year, beginning on May 15,
2011.
		
	Issue Price:	  	100%, plus accrued interest, if any, from November 19, 2010.
		
	Closing Stock Price:	  	$26.12 on NASDAQ as of November 15, 2010.
		
	Conversion Premium:	  	Approximately 30% above the Closing Stock Price.
		
	Initial Conversion Price:	  	Approximately $33.96 per share of the Issuer’s common stock.
		
	Initial Conversion Rate:	  	29.4499 shares of the Issuer’s common stock per $1,000 principal amount of notes.
		
	Conversion Trigger Price:	  	Approximately $44.15, which is 130% of the Initial Conversion Price.
		
	Joint Book-Running Managers:	  	BofA Merrill Lynch and RBS.
		
	Trade Date:	  	November 15, 2010.
		
	Expected Settlement Date:	  	November 19, 2010.
		
	CUSIP Number:	  	483548 AD5
		
	Ranking:	  	The notes will be general unsecured obligations of Kaman Corporation. On a pro forma basis, as of October 1, 2010, after giving effect to the issuance of the notes and the use of
proceeds, we would have had approximately $83.3 million outstanding secured indebtedness, substantially all of which will represent borrowings under our amended and restated revolving credit agreement and term loan credit agreement, $100.8 million
of outstanding senior unsecured indebtedness and no subordinated indebtedness. As of October 1, 2010, in addition to our domestic subsidiaries serving as guarantors under our amended and restated revolving credit agreement and amended and restated
term loan credit agreement, our subsidiaries had $0.8 million of outstanding indebtedness and other liabilities (excluding intercompany liabilities).


  
 Sch
C - 1 









			
		
	Adjustment to Conversion Rate Upon a Conversion in Connection With a Make-Whole Fundamental Change:	  	The following table sets forth the stock prices and effective dates and the number of additional shares by which the conversion rate will be increased for a holder that converts a
note in connection with a make-whole fundamental change having such effective date and stock price:

  

																																													
	 Stock Price
	 
	 Effective Date
	  	$26.12	 	  	$30.00	 	  	$35.00	 	  	$40.00	 	  	$45.00	 	  	$50.00	 	  	$60.00	 	  	$70.00	 	  	$80.00	 	  	$90.00	 	  	$100.00	 
	 11/19/2010
	  	 	8.8349	  	  	 	6.3895	  	  	 	4.2649	  	  	 	3.0809	  	  	 	2.3455	  	  	 	1.8655	  	  	 	1.2944	  	  	 	0.9804	  	  	 	0.7847	  	  	 	0.6445	  	  	 	0.5373	  
	 11/15/2011
	  	 	8.8349	  	  	 	6.3662	  	  	 	4.2029	  	  	 	2.9480	  	  	 	2.1879	  	  	 	1.7046	  	  	 	1.1559	  	  	 	0.8668	  	  	 	0.6923	  	  	 	0.5672	  	  	 	0.4726	  
	 11/15/2012
	  	 	8.8349	  	  	 	6.3241	  	  	 	4.0684	  	  	 	2.7519	  	  	 	1.9795	  	  	 	1.5068	  	  	 	0.9949	  	  	 	0.7418	  	  	 	0.5905	  	  	 	0.4842	  	  	 	0.4038	  
	 11/15/2013
	  	 	8.8349	  	  	 	6.2694	  	  	 	3.8441	  	  	 	2.4767	  	  	 	1.7099	  	  	 	1.2622	  	  	 	0.8063	  	  	 	0.6016	  	  	 	0.4790	  	  	 	0.3933	  	  	 	0.3281	  
	 11/15/2014
	  	 	8.8349	  	  	 	6.0833	  	  	 	3.4617	  	  	 	2.0822	  	  	 	1.3559	  	  	 	0.9630	  	  	 	0.6023	  	  	 	0.4523	  	  	 	0.3629	  	  	 	0.2991	  	  	 	0.2498	  
	 11/15/2015
	  	 	8.8349	  	  	 	5.6165	  	  	 	2.8697	  	  	 	1.5328	  	  	 	0.9085	  	  	 	0.6137	  	  	 	0.3857	  	  	 	0.2960	  	  	 	0.2394	  	  	 	0.1972	  	  	 	0.1640	  
	 11/15/2016
	  	 	8.8349	  	  	 	4.7769	  	  	 	1.9173	  	  	 	0.7770	  	  	 	0.3911	  	  	 	0.2653	  	  	 	0.1900	  	  	 	0.1522	  	  	 	0.1246	  	  	 	0.1032	  	  	 	0.0861	  
	 11/15/2017
	  	 	8.8349	  	  	 	3.8834	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  


  
 Sch
C - 1 








 The exact stock prices and effective dates may not be set forth in the table above, in which
case: 
  

	 	•	 	 if the stock price is between two stock prices listed in the table or the effective date is between two effective dates listed in the table, the number
of additional shares will be determined by a straight-line interpolation between the number of additional shares set forth for the higher and lower stock prices and the earlier and later effective dates, as applicable, based on a 365-day year.



  

	 	•	 	 if the stock price is greater than $100.00 per share (subject to adjustment in the same manner as the stock prices set forth in the column headings of
the table above), no additional shares will be added to the conversion rate. 


  

	 	•	 	 if the stock price is less than $26.12 per share (subject to adjustment in the same manner as the stock prices set forth in the column headings of the
table above), no additional shares will be added to the conversion rate. 


 Notwithstanding the foregoing, in
no event will the conversion rate exceed 38.2848 shares per $1,000 principal amount of notes, subject to adjustments in the same manner as the conversion rate as set forth in the Preliminary Offering Memorandum under “Description of
Notes—Conversion Rates—Conversion Rate Adjustments.” 
 Capitalization 

The following table sets forth our unaudited cash, cash equivalents, short-term and long-term cash investments and capitalization as of
October 1, 2010: 
  

	 	•	 	 on an actual basis; and 


  

	 	•	 	 on an as adjusted basis giving effect to (i) the issuance of $100 million of notes and the receipt of the net proceeds from the sale of the notes
after payment of the initial purchasers’ commissions and estimated offering expenses payable by us, (ii) the use of a portion of the proceeds from this offering to fund the net cost of the convertible note hedge and warrant transactions,
and (iii) the application of such net proceeds (assuming the use of $64.3 million of the net proceeds from this offering to repay portions of our amended and restated revolving credit agreement, which amounts we may re-borrow), as if such
events took place on October 1, 2010, reflecting the application of ASC 470-20 “Debt with Conversion and Other Options,” which requires issuers to separately account for the debt and equity components of convertible debt instruments
that allow for cash settlement. 


 In accordance with ASC 470-20 “Debt with Conversion and Other
Options,” we estimate that $100 million of the aggregate principal amount of the notes will be recognized (and, to the extent applicable, reflected in the table below ) as follows (in thousands): 

 

					
	 Equity component
	  	$	 11,590	  
	 Liability component:
	  			
	 Principal
	  	$	100,000	  
	 Less: debt discount
	  	 	(11,590	) 
		  	 	 	 
	 Net carrying amount
	  	$	 88,410	  
		  	 	 	 


  
 Sch
C - 1 








 You should read this table together with our consolidated financial statements and related
notes contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and our Quarterly Report on Form 10-Q for the fiscal quarter ended October 1, 2010, which are incorporated by reference in the Preliminary
Offering Memorandum. 
  

									
	 	  	As of October 1, 2010	 
	 	  	Actual	 	 	As Adjusted	 
	 Cash and cash equivalents
	  	$	11,946	  	 	$	34,123	  
		  	 	 	 	 	 	 	 
	 Debt
	  				 			
	 Notes payable
	  	$	768	  	 	$	768	  
	 Current portion of long-term debt
	  	 	5,000	  	 	 	5,000	  
	 Notes offered hereby
	  	 	—  	  	 	 	88,410	  
	 Long-term debt, excluding current portion
	  	 	100,550	  	 	 	36,250	  
		  	 	 	 	 	 	 	 
	 Total debt
	  	$	106,318	  	 	$	130,428	  
		  	 	 	 	 	 	 	 
	 Shareholders’ equity
	  				 			
	 Capital stock, $1 par value per share:
	  				 			
	 Preferred stock, 200,000 shares authorized; none outstanding
	  	$	—  	  	 	$	—  	  
	 Common stock, 50,000,000 shares authorized, voting, 26,042,901 issued (1)
	  	 	26,043	  	 	 	26,043	  
	 Additional paid-in capital
	  	 	94,737	  	 	 	96,008	  
	 Retained earnings
	  	 	314,792	  	 	 	314,792	  
	 Accumulated other comprehensive income (loss)
	  	 	(81,283	) 	 	 	(81,283	) 
	 Less 63,130 shares of common stock held in treasury, at cost
	  	 	(866	) 	 	 	(866	) 
		  	 	 	 	 	 	 	 
	 Total shareholders’ equity
	  	$	353,423	  	 	$	354,694	  
		  	 	 	 	 	 	 	 
	 Total Capitalization
	  	$	459,741	  	 	$	485,122	  
		  	 	 	 	 	 	 	 

  

	(1)	The number of shares outstanding does not include the following: 

  

	 	•	 	 1,032,522 shares of common stock issuable upon exercise of stock options outstanding as of October 1, 2010 under our 2003 Stock Incentive Plan
with a weighted average exercise price of approximately $20.58 per share; 


  

	 	•	 	 307,167 shares of common stock issuable upon the vesting of restricted stock awards granted to employees and outstanding as of October 1, 2010
under our 2003 Stock Incentive Plan, with a weighted average grant date fair value of $22.80 per share; 


  

	 	•	 	 21,700 shares of common stock issuable upon the settlement of stock appreciation rights outstanding as of October 1, 2010 under our 2003 Stock
Incentive Plan, with a weighted average exercise price of approximately $10.66 per share; 


  

	 	•	 	 1,101,834 shares of common stock reserved for future issuance under our 2003 Stock Incentive Plan as of October 1, 2010;



  

	 	•	 	 725,102 shares of common stock reserved for future sale under our Employees Stock Purchase Plan as of October 1, 2010; and



  

	 	•	 	 shares of our common stock issuable upon conversion of the notes offered hereby or exercise of hedge warrants. 



  
 Sch
C - 1 








 This communication is intended for the sole use of the person to whom it is provided by the sender. This
material is confidential and is for your information only and is not intended to be used by anyone other than you. This information does not purport to be a complete description of the notes or the offering. 

This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these
securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state. 
 Neither the notes nor any shares of common stock issuable upon conversion of the notes have been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the
securities laws of any jurisdiction. Unless they are registered, the notes and any share of common stock issuable upon conversion of the notes may be offered only in transactions that are exempt from registration under the Securities Act and the
securities laws of any other jurisdiction. Accordingly, the notes are being offered and sold only to “qualified institutional buyers” (as defined in Rule 144A under the Securities Act). For further details about eligible offerees and
resale restrictions, see the section of the Preliminary Offering Memorandum captioned “Notice to Investors.” 
 A copy of the
final offering memorandum for the offering of the notes may be obtained by contacting: BofA Merrill Lynch, 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department. 
 ANY DISCLAIMER OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS
COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM. 

  
 Sch
C - 1 








 SCHEDULE C 
 Issuer Written Information 
 Final Term Sheet in the form set forth on Schedule B


  
 Sch C - 1









 SCHEDULE D 
 Subsidiaries 
 Kaman Aerospace Group, Inc. 

Kaman Aerospace Corporation 
 Kamatics
Corporation 
 Kaman Precision Products, Inc. 
 RWG Frankenjura-Industrie Flugwerklager GmbH 
 Kaman UK Holdings Limited 

Brookhouse Holdings Limited 
 Brookhouse Group
Holdings Limited 
 Brookhouse 2004 Limited 
 Brookhouse Tooling Limited 
 Brookhouse Composites Limited 

Brookhouse Aerospace Limited 
 Kaman Industrial
Technologies Corporation 
 Minarik Corporation 

  
 Sch D - 1









 SCHEDULE E 
 List of Persons and Entities Subject to Lock-up 
 Brian E. Barents 

E. Reeves Callaway III 
 Candace A. Clark

 William C. Denninger 
 Ronald M.
Galla 
 Karen M. Garrison 
 A. William
Higgins 
 Edwin A. Huston 
 Neal J.
Keating 
 Eileen S. Kraus 
 George E.
Minnich 
 Thomas W. Rabaut 
 Gregory L.
Steiner 
 Richard J. Swift 
 John J.
Tedone 
 Jack Cahill 
 Stephen J.
Smidler 

  
 Sch E - 1









 Exhibit A – 1 
 FORM OF OPINION OF COMPANY’S COUNSEL 
 TO BE DELIVERED PURSUANT TO SECTION 5(b)

 [TO BE ATTACHED] 

  
 A – 1 - 1









 Exhibit A – 2 
 FORM OF OPINION OF COMPANY’S CHIEF LEGAL COUNSEL 
 TO BE DELIVERED PURSUANT TO
SECTION 5(b) 
 [TO BE ATTACHED] 

  
 A – 2 - 1









 Exhibit A – 3 
 FORM OF OPINION OF COMPANY’S LOCAL COUNSEL 
 TO BE DELIVERED PURSUANT TO
SECTION 5(c) 
 [TO BE ATTACHED] 

  
 A – 3 - 1









 Exhibit B 
 FORM OF LOCK-UP TO BE DELIVERED PURSUANT TO SECTION 5(h) 
 November 15, 2010

 Merrill Lynch, Pierce, Fenner & Smith Incorporated, 
 RBS Securities Inc. 
   as Representatives of the several 

  Initial Purchasers to be named in the 

  within-mentioned Purchase Agreement 

c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated 
 One Bryant Park 
 New York, New York 10036 

 

	 	Re:	Proposed Public Offering by Kaman Corporation 

 Dear Sirs: 
 The undersigned, a stockholder [and an officer and/or director] of
Kaman Corporation, a Connecticut corporation (the “Company”), understands that Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) and RBS Securities Inc. propose to enter into a Purchase Agreement (the
“Purchase Agreement”) with the Company providing for the offering (the “Offering”) of $100,000,000 aggregate principal amount of the Company’s 3.25% Convertible Senior Notes due 2017 (the “Securities”). In
recognition of the benefit that such Offering will confer upon the undersigned as a stockholder [and an officer and/or director] of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the undersigned agrees with each initial purchaser to be named in the Purchase Agreement that, during a period of 90 days from the date of the Purchase Agreement (the “Lock-up Period”), the undersigned will not, without the
prior written consent of Merrill Lynch, directly or indirectly, (a) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or
otherwise dispose of or transfer any shares of the Company’s common stock, par value $1.00 per share (the “Common Stock”), or any securities convertible into or exchangeable or exercisable for Common Stock, whether now owned or
hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the “Lock-Up Securities”), or exercise any right with respect to the registration of any of
the Lock-up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended, or (b) enter into any swap or any other agreement or any transaction that transfers, in whole
or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash or otherwise. The foregoing sentence
shall not apply to: 
 (i) transactions relating to shares of Common Stock acquired in open market transactions
after the completion of the Public Offering, or the exercise of any stock option to purchase shares of Common Stock pursuant to any benefit plan of the Company; 

  
 B-1









 (ii) transfers of shares of Common Stock or any security directly or
indirectly convertible into or exercisable or exchangeable for Common Stock as a bona fide gift or in connection with estate planning, including but not limited to, dispositions to any trust for the direct or indirect benefit of the undersigned
and/or the immediate family of the undersigned and dispositions from any grantor retained annuity trust established for the direct benefit of the undersigned and/or a member of the immediate family of the undersigned, or by will or intestacy;

 (iii) distributions of shares of Common Stock or any security directly or indirectly convertible into or
exercisable or exchangeable for Common Stock to limited partners, members, stockholders or affiliates of the undersigned, or to any partnership, corporation or limited liability company controlled by the undersigned or by a member of the immediate
family of the undersigned; or 
 (iv) the establishment of a trading plan pursuant to Rule 10b 5-1 under the 1934
Act for the transfer of shares of Common Stock, provided that such plan does not provide for the transfer of Common Stock during the Lock-Up Period; 
 provided, however, that (a) in the case of any transfer or distribution pursuant to clause (ii) or (iii), each donee or distributee shall sign and deliver a lock-up letter agreement
substantially in the form of this letter agreement (the “Lock-Up Agreement”) and (b) in the case of any transaction pursuant to clauses (i), (ii), (iii) or (iv), such transaction is not required to be reported during the Lock-Up
Period by anyone in any press release, public report or filing with the Securities and Exchange Commission or otherwise (other than a required filing on Form 5, Schedule 13D or Schedule 13G (or 13D-A or 13G-A) and no such press release, public
report or filing shall be made voluntarily during the Lock-Up Period. In addition, the undersigned agrees that, without the prior written consent of Merrill Lynch, it will not, during the Lock-Up Period, make any demand for or exercise any right
with respect to, the registration of any shares of Common Stock or any security directly or indirectly convertible into or exercisable or exchangeable for Common Stock. 
 Notwithstanding the foregoing, if: 
 (1) during the last 17 days of the Lock-up
Period, the Company issues an earnings release or material news or a material event relating to the Company occurs; or 
 (2)
prior to the expiration of the Lock-up Period, the Company announces that it will release earnings results or becomes aware that material news or a material event will occur during the 16-day period beginning on the last day of the Lock-up Period,

 Merrill Lynch may extend, by written notice to the Company, the restrictions imposed by this lock-up agreement until the expiration of the
18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event, as applicable. 
 The undersigned hereby acknowledges and agrees that written notice of any extension of the Lock-up Period pursuant to the previous paragraph will be delivered by Merrill Lynch to the Company (in
accordance with Section 12 of the Purchase Agreement) and that any such notice properly delivered will be deemed to have been given to, and received by, the undersigned. The undersigned further agrees that, prior to engaging in any transaction
or taking any other action that is subject to the terms of this lock-up agreement during the period from the date of this lock-up agreement to and including the 34th day following the expiration of the initial Lock-up Period, it will give notice thereof to the Company and will not
consummate such transaction or take any such action unless it has received written confirmation from the Company that the Lock-up Period (as may have been extended pursuant to the previous paragraph) has expired. 

  
 B-2









 The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company’s transfer agent and registrar against the transfer of the Lock-Up Securities except in compliance with the foregoing restrictions. 
 This Lock-Up Agreement shall automatically terminate upon the earliest to occur, if any, of (1) either Merrill Lynch, on the one hand, or the Company, on the other hand, advising the other in
writing, prior to the execution of the Purchase Agreement, that they have determined not to proceed with the Offering, (2) termination of the Purchase Agreement before the sale of any Securities to the Initial Purchasers, or
(3) December 31, 2010, in the event that the Purchase Agreement has not been executed by that date. 
  

			
	Very truly yours,
		
	Signature:	 	 



			
		
	Print Name:	 	 



  
 B-3